Australia's most trusted
source of pharma news
Thursday, 22 January 2026
Posted 21 January 2026 PM
Pfizer has sold out of ViiV, taking $2.781 billion (US$1.875 billion) for the last of its holdings of the company it co-founded with GSK in 2009.
Japanese pharma Shionogi will increase its stake in the company by buying Pfizer's ll.7 per cent share in the HIV-focused pharma, and also paying GSK a special dividend of $371 million (US$250 million), payable in British Pounds.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.